Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH) has announced that its subsidiary, Shanghai Sine Promod Pharmaceutical Co., Ltd., has obtained a Drug Registration Certificate from the National Medical Products Administration for Omeprazole and Sodium Bicarbonate for Oral Suspension (I), granting approval for production.
The newly approved product, which contains 20mg of omeprazole and 1680mg of sodium bicarbonate per sachet, is primarily indicated for the short-term treatment of active duodenal ulcers and gastroesophageal reflux disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments